ADMA_OUT_1 [2025-04-29 06:29:54 -0400] 5661 Bytes | 1614 tokens | Cum: 1614 tkns (20.18% of 8k)
==========================================================================

Sensor readings are abnormal, Captain. ADMA Biologics (ADMA) rising sharply—from $21.86 to $24.53. It is now 6:29 AM on Tue Apr 29, 2025. Recommend deeper scan before action is taken.

--- COMPANY PROFILE ---
Company: ADMA Biologics (ADMA)
IPO: 2013-10-17 (11 Years Ago)
Market Cap: $4,441,026,219
Shares Outstanding: 237,620,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Here’s a list of headlines for ADMA Biologics:

Today 02:01AM - Why ADMA Biologics, Inc. (ADMA) Surged on Monday
Apr-28-25 04:05PM - IBD 50's Top Seed, ADMA, Just Rocketed On A New FDA Approval
Apr-28-25 04:05PM 07:00AM - ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
Apr-25-25 01:52PM - Tech Stocks Reclaim Dominance In Elite List Led By Palantir
Apr-25-25 01:52PM 10:41AM - GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline
Apr-24-25 11:54AM - BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook
Apr-23-25 08:48PM - ADMA Biologics, Inc. (ADMA): Among Takeover Rumors Hedge Funds Are Buying
Apr-23-25 08:48PM 06:14PM - Is ADMA Biologics, Inc. (ADMA) the Best Multibagger Stock to Buy According to Billionaires?
Apr-23-25 08:48PM 05:50PM - Adma Biologics (ADMA) Gains But Lags Market: What You Should Know
Apr-22-25 01:28AM - Why ADMA Biologics Inc. (ADMA) Performed Worst On Monday?
Apr-17-25 05:50PM - Adma Biologics (ADMA) Beats Stock Market Upswing: What Investors Need to Know
Apr-17-25 05:50PM 09:17AM - GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP
Apr-17-25 05:50PM 09:09AM - ADMA Biologics (ADMA): Among Louis Navellier's New Stock Picks
Apr-16-25 09:48AM - MURA Soars as it Explores Strategic Options Post Cancer Study Failures
Apr-16-25 09:48AM 09:30AM - Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
Apr-16-25 09:48AM 08:52AM - DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up
Apr-16-25 09:48AM 06:45AM - Why ADMA Biologics, Inc. (ADMA) Skyrocketed On Tuesday?
Apr-15-25 12:27PM - VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study
Apr-15-25 12:27PM 10:42AM - Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag
Apr-15-25 12:27PM 09:40AM - Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
Apr-15-25 12:27PM 09:35AM - Adma Biologics (ADMA) Just Overtook the 20-Day Moving Average
Apr-15-25 12:27PM 09:18AM - Ironwood Shares Tank on Regulatory Update for Apraglutide

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-07T11:00:00Z - ADMA Biologics Statement on Tariffs
B2 - 2025-03-04T18:50:00Z - BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed 10-K and KPMG Evaluation of Controls
B3 - 2024-11-02T10:18:00Z - BFA Law is Investigating ADMA BIOLOGICS for Securities Fraud after Stock Plummets 20%; Contact the Firm if You Suffered Losses (Nasdaq:ADMA)
B4 - 2024-10-27T12:06:00Z - ADMA FRAUD ALERT: BFA Law Notifies ADMA Biologics Investors of Ongoing Securities Fraud Investigation after Auditor Resigns and Urges You to Contact the Firm (Nasdaq:ADMA)
B5 - 2024-10-19T10:28:00Z - ADMA INVESTIGATION UPDATE: ADMA Biologics Investors are Notified of Securities Fraud Investigation into Auditor Resignation; Contact BFA Law if You Lost Money (Nasdaq:ADMA)
B6 - 2024-10-17T15:00:00Z - ADMA Biologics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for ADMA Biologics (ADMA).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

ADMA_OUT_3 [2025-04-29 06:29:55 -0400] 914 Bytes | 252 tokens | Cum: 1868 tkns (23.35% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed 10-K and KPMG Evaluation of Controls**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/04/3036885/23044/en/BREAKING-Block-Leviton-Investigating-ADMA-Biologics-Inc-for-Securities-Fraud-Violations-Following-Delayed-10-K-and-KPMG-Evaluation-of-Controls.htmlADMA Biologics, Inc. is being investigated by Block & Leviton for potential securities law violations following a delay in filing its Form 10-K and an ongoing audit by KPMG focused on evaluating internal controls.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADMA_OUT_5 [2025-04-29 06:29:56 -0400] 899 Bytes | 276 tokens | Cum: 2146 tkns (26.82% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-28T17:52:48Z - What's Going On With ADMA Stock Monday? - ADMA Biologics (NASDAQ:ADMA)...
A2 - 2025-04-28T16:39:51Z - Stocks making the biggest moves midday: Plug Power, Nvidia, Peloton and more...
A3 - 2025-04-28T14:27:14Z - Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday - ADMA ...
A4 - 2025-04-28T14:29:59Z - ADMA Biologics Shares Hit 52-Week High After FDA Approval...
A5 - 2025-04-28T14:16:44Z - ADMA Biologics Shares Hit 52-Week High After FDA Approval...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ADMA_OUT_7 [2025-04-29 06:29:56 -0400] 1181 Bytes | 297 tokens | Cum: 2445 tkns (30.56% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**What's Going On With ADMA Stock Monday? - ADMA Biologics (NASDAQ:ADMA)**Date: 2025-04-28Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/25/04/45048010/whats-going-on-with-adma-stock-mondayFeel unsure about the market's next move? Copy trade alerts from Matt Maley -- a Wall Street veteran who consistently finds profits in volatile markets. Claim your 7-day free trial now.

ADMA Biologics Inc. ADMA shares are trading higher Monday following the Food and Drug Administration's (FDA) approval of its yield enhancement process.

What To Know: ADMA's yield enhancement process has demonstrated the ability to increase production yields by approximately 20% from the same starting plasma volume.

"This approval represents a pivotal milestone for ADMA, unlocking the opportunity for meaningful acceleration in our revenue and earnings trajecto

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADMA_OUT_9 [2025-04-29 06:29:57 -0400] 1181 Bytes | 292 tokens | Cum: 2739 tkns (34.24% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): ry beginning in late 2025 and accelerating further into 2026 and beyond," said Adam Grossman, President and CEO of ADMA.

Grossman added that the company is focused on advancing its internal Research and Development platform to further optimize production capabilities and develop new pipeline programs, most notably SG-001, an early-stage antibody therapy targeting S. pneumoniae.

What Else: The company is expected to report first-quarter earnings on May 12th. Analysts' estimate earnings per share of 16 cents and revenue of $116.40 million.

Related Link: Nuvve Expands Beyond EVs With Bold Bitcoin, Crypto Investment Arm

ADMA Price Action: At the time of publication, ADMA share are trading 9.79% higher at $24.00, according to data from Benzinga Pro.

Image: via Shutterstock

ADMAADMA Biologics Inc$23.999.75%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on a

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADMA_OUT_11 [2025-04-29 06:29:58 -0400] 458 Bytes | 127 tokens | Cum: 2868 tkns (35.85% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): ny stock - anytime.

Reveal Full ScoreEdge RankingsMomentum98.55Growth-Quality-Value15.35Price TrendShortMediumLongOverviewMarket News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADMA_OUT_13 [2025-04-29 06:29:59 -0400] 509 Bytes | 120 tokens | Cum: 2990 tkns (37.38% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S4 - 2025-03-18 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

##TABLE_END

The following discussion of our financial condition and results of operations should be read in conjunction with the CONS financial statements and notes thereto in...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ADMA_OUT_15 [2025-04-29 06:30:00 -0400] 1181 Bytes | 253 tokens | Cum: 3245 tkns (40.56% of 8k)
==========================================================================

Showing S4 (chunk 1 of 6): S4:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

##TABLE_END

The following discussion of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and notes thereto included elsewhere in this Annual Report on Form 10-K. The various sections of this discussion contain a number of forward-looking statements, all of which are based on our current expectations and could be materially affected by the uncertainties and risk factors described throughout this Annual Report. See Special Note Regarding Forward-Looking Statements. Our actual results may differ materially.

OVERVIEW

Our Business

ADMA Biologics, Inc. (the Company, ADMA, we, us or our) is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADMA_OUT_17 [2025-04-29 06:30:00 -0400] 1181 Bytes | 267 tokens | Cum: 3514 tkns (43.92% of 8k)
==========================================================================

Showing S4 (chunk 2 of 6): treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.

Through our ADMA BioManufacturing business segment, we currently have three products with U.S. Food and Drug Administration (the FDA) approval, all of which are currently marketed and commercially available: (i) ASCENIV (Immune Globulin Intravenous, Human slra 10% Liquid), an Intravenous Immune Globulin (IVIG) product indicated for the treatment of Primary Humoral Immunodeficiency (PI), also known as Primary Immunodeficiency Disease (PIDD) or Inborn Errors of immunity in adults and adolescents, for which we received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADMA_OUT_19 [2025-04-29 06:30:01 -0400] 1181 Bytes | 283 tokens | Cum: 3799 tkns (47.49% of 8k)
==========================================================================

Showing S4 (chunk 3 of 6): ; (ii) BIVIGAM (Immune Globulin Intravenous, Human), an IVIG product indicated for the treatment of PI, and for which we received FDA approval on May 9, 2019 and commenced commercial sales in August 2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing HBsAg and other listed exposures to Hepatitis B. We seek to develop a pipeline of plasma-derived therapeutics, including a product based on our most recently approved patent application under U.S. Patent Nos. 10,259,865 and 11,084,870 related to methods of treatment and prevention of S. pneumonia infection for an immunoglobulin manufactured to contain standardized antibodies to numerous serotypes of S. pneumoniae . We have successfully completed production of a pilot-scale batch and are conducting animal studies for our S. pneumoniae hyperimmune globulin pro

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADMA_OUT_21 [2025-04-29 06:30:02 -0400] 1181 Bytes | 254 tokens | Cum: 4055 tkns (50.69% of 8k)
==========================================================================

Showing S4 (chunk 4 of 6): gram, SG-001. Our products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases.

We manufacture these products at our FDA-licensed, plasma fractionation and purification facility located in Boca Raton, Florida with a peak annual processing capability of up to 600,000 liters (the Boca Facility). Based on current production yields, our completed and ongoing supply chain enhancements and capacity expansion initiatives, we believe this facility has the potential to produce sufficient quantities of our immune globulin (IG) products representing projected annual revenues greater than $490 million in 2025 and $605 million in 2026. These revenue targets translate to potential fiscal year 2025 and 2026 Adjusted Net Income exceeding $175 million and $235 million, respectively, and

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADMA_OUT_23 [2025-04-29 06:30:03 -0400] 1181 Bytes | 243 tokens | Cum: 4300 tkns (53.75% of 8k)
==========================================================================

Showing S4 (chunk 5 of 6): Adjusted EBITDA exceeding $225 million and $305 million, respectively. The foregoing financial targets do not account for the potential FDA approval of our innovative yield enhancement production process described below.

In December 2024, we successfully submitted a Prior Approval Supplement (the PAS) for potential approval of our innovative yield enhancement production process. Following FDA review of the submission, we anticipate receiving FDA approval by mid-2025, with potential revenue and earnings accretion expected in the second half of the year. This innovative process has demonstrated an ability to increase production yields by approximately 20% from the same starting plasma volume, potentially driving significant increases to financial targets, if approved.

Through our ADMA BioCenters subsidiary, we currently operate ten source plasma collection facilities in the U.S., all of

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADMA_OUT_25 [2025-04-29 06:30:04 -0400] 790 Bytes | 176 tokens | Cum: 4478 tkns (55.97% of 8k)
==========================================================================

Showing S4 (chunk 6 of 6): which hold FDA licenses. This business unit, which we refer to as our Plasma Collection Centers business segment, provides us with the blood plasma required for the manufacture of our products, and also allows us to sell certain quantities of source and hyperimmune plasma to third-party customers for further manufacturing. In addition, three of our FDA-approved plasma collection centers also have approvals from the Korean Ministry of Food and Drug Safety (MFDS), as well as FDA approval to operate a ...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ADMA_OUT_27 [2025-04-29 06:30:10 -0400] 7715 Bytes | 2248 tokens | Cum: 6728 tkns (84.10% of 8k)
==========================================================================

This is our set of metrics for ADMA Biologics.
Please analyze the numbers.

+--------------------+-----------------------+-------------------------+-----------------------+
| Volume: 10,267,679 | Perf Month: 20.86% | Option/Short: Yes / Yes | Sales Y/Y TTM: 65.15% |
+--------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 3.19M | Perf Quarter: 51.39% | Short Float: 5.76% | ROE: 81.65% |
+--------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 3.34 | Index: RUT | Short Ratio: 4.15 | ROI: 45.98% |
+--------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 67.49 | Market Cap: 5.85B | Short Interest: 13.26M | Sales Surprise: 4.24% |
+--------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 1.55 | Shs Outstand: 236.62M | Beta: 0.55 | EPS Surprise: -6.07% |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA20: 20.22% | Shs Float: 230.23M | Sales Q/Q: 59.06% | P/E: 30.28 |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA50: 30.67% | Inst Own: 86.06% | Sales past 5Y: 71.73% | Earnings: Mar 03 AMC |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA200: 38.33% | Insider Own: 3.49% | Employees: 685 | |
+--------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: 24.80% | Insider Trans: -1.26% | Debt/Eq: 0.24 | |
+--------------------+-----------------------+-------------------------+-----------------------+

The next section covers any insider trading by ADMA Biologics officers or majority shareholders (if available).

Inside Trans: ADMA BIOLOGICS, INC. (ADMA) by Grossman Adam S (President and CEO) on 2025-04-15
- Common Stock: 15000 shares at $5.4 (D)
- Common Stock: 15000 shares at $21.46 (D)
- Common Stock: 6000 shares at $21.46 (D)
- Stock Option (right to buy): 15000 shares at $0 (D)

Inside Trans: ADMA BIOLOGICS, INC. (ADMA) by Kestenberg-Messina Kaitlin M. (COO and SVP, Compliance) on 2025-04-01
- Common Stock: 18920 shares at $19.42 (D)

Inside Trans: ADMA BIOLOGICS, INC. (ADMA) by Grossman Adam S (President and CEO) on 2025-03-19
- Common Stock: 15000 shares at $5.4 (D)
- Common Stock: 15000 shares at $18.92 (D)
- Common Stock: 6000 shares at $18.92 (D)
- Common Stock: 15000 shares at $0 (D)

Inside Trans: ADMA BIOLOGICS, INC. (ADMA) by Kestenberg-Messina Kaitlin M. (COO and SVP, Compliance) on 2025-03-06
- Common Stock: 8881 shares at $16.91 (D)
- Common Stock: 3935 shares at $17.02 (D)

Inside Trans: ADMA BIOLOGICS, INC. (ADMA) by Grossman Adam S (President and CEO) on 2025-03-06
- Common Stock: 56438 shares at $16.91 (D)
- Common Stock: 29513 shares at $17.02 (D)

Inside Trans: ADMA BIOLOGICS, INC. (ADMA) by Tade Brad L. (CFO and Treasurer) on 2025-02-26
- Common Stock: 5280 shares at $15.78 (D)

Inside Trans: ADMA BIOLOGICS, INC. (ADMA) by Kestenberg-Messina Kaitlin M. (COO and SVP, Compliance) on 2025-02-25
- Common Stock: 1855 shares at $15.44 (D)

Inside Trans: ADMA BIOLOGICS, INC. (ADMA) by Grossman Adam S (President and CEO) on 2025-02-25
- Common Stock: 18018 shares at $15.44 (D)
- Common Stock: 54867 shares at $15.78 (D)

Inside Trans: ADMA BIOLOGICS, INC. (ADMA) by Salas Eduardo Rene (Unknown Title) on 2025-02-19
- Common Stock: 10889 shares at $0 (D)
- Stock Option (right to buy): 16279 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 426454000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': 197673000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 24.51
Average Volume: 4002208.25
30-Day High: 24.51
30-Day Low: 17.86

[Detailed Financials: TTM 2024]
- Total Assets: $488,678,000.00
- Total Liabilities: $139,660,000.00
- Total Equity: $349,018,000.00
- Current Assets: $331,410,000.00
- Current Liabilities: $55,542,000.00

[Income Statement: TTM 2024]
- Revenue: $426,454,000.00
- Net Income: $197,673,000.00
- Gross Profit: $219,553,000.00
- Operating Income: $138,983,000.00
- Earnings Per Share (EPS): 0.85

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $51,795,000.00

[Detailed Financials: FY 2024]
- Total Assets: $488,678,000.00
- Total Liabilities: $139,660,000.00
- Total Equity: $349,018,000.00
- Current Assets: $331,410,000.00
- Current Liabilities: $55,542,000.00

[Income Statement: FY 2024]
- Revenue: $426,454,000.00
- Net Income: $197,673,000.00
- Gross Profit: $219,553,000.00
- Operating Income: $138,983,000.00
- Earnings Per Share (EPS): 0.85

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $51,795,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of ADMA Biologics (ADMA).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about ADMA Biologics.

2) MARKET_SCORE[]
This conversation was initiated because ADMA is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for ADMA.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, ADMA could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect ADMA to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of ADMA Biologics.

11) ETHICAL_RATING[]
Rate ADMA Biologics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of ADMA Biologics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

ADMA_IN_29 [2025-04-29 06:30:10 -0400] 126 Bytes | 29 tokens | Cum: 6963 tkns (87.04% of 8k)
==========================================================================

====================================
[2025-04-29 06:30:10] # Analysis Completed
Elapsed Time: 17.08 seconds